An interventional study of Robotic pancreatoduodenectomy and open pancreatoduodenectomy in Pancreas Neoplasms, sponsored by Hospital del Mar. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Hospital del Mar · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Pancreatic Neoplasms with a site in Spain — 46 open to participants now, 69 under way, 11 of them phase 3. Pancreatic Neoplasms · Spain.
Among the 202 studies in Pancreatic Neoplasms with a site in Spain, this one is the 93rd largest by planned enrollment of the 174 interventional ones that give a count, is one of 15 that started in 2025, is one of 24 with no phase, reaches primary completion later than 36 of the 68 other live ones, and was the 177th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →46 of the 202 studies in Pancreatic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Theriva Biologics SL · Sites in Spain
Ages 18+
Bristol-Myers Squibb · Sites in Spain, United States, Belgium and 10 more countries
Ages 18+
Immuneering Corporation · Sites in Spain, United States, Australia and 6 more countries
Ages 18+
Blueprint Medicines Corporation · Sites in Spain, United States
Ages 18+
Incyte Corporation · Sites in Spain, United States, Australia and 19 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 89 · Phase 3 30 · Phase 4 3
First in 2002; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 146 across the 174 interventional studies, 312 across the 26 observational. Of the 116 that completed or were terminated, 50 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
142 of 202 have an industry lead sponsor. The 10 most frequent:
Hospital del Mar is the lead sponsor of 45 studies on the registry; 17 are open to participants now.
Hospital del Mar has 3 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
18 of the studies in Pancreatic Neoplasms with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT06695845Jazz PharmaceuticalsA Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | 2026-12-31 |
| NCT04954599Maastricht University Medical CenterPhase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | 2027-02 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT07284277Clinica Universidad de Navarra, Universidad de NavarraTTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) | 2027-03 |
Add all 18 to your calendar (.ics) → With an account.
Among the 202 studies in Pancreatic Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pancreatic surgery, specifically pancreatoduodenectomy (PD), is a complex procedure often required for patients with pancreatic or other periampullary cancers. In recent years, minimally invasive techniques have become more popular, especially robotic-assisted surgery. However, there are limited studies comparing robotic surgery to traditional open surgery.
This is a national, multicenter study in Spain comparing the outcomes of robotic versus open pancreatoduodenectomy (PD). The main goal is to assess complications within 90 days after surgery. This study is important because it will provide evidence on which approach is safer and more effective for patients.
The study follows a **prospective, randomized, and multicenter design**, meaning patients are assigned to either robotic or open surgery randomly, and multiple hospitals are involved. The study will include all eligible patients undergoing planned PD surgery, either by robotic or open technique.
To be included in the study, patients must meet these conditions:
Who Cannot Participate?
Patients will **not** be included if they:
The main outcome measured will be the **Comprehensive Complication Index (CCI), a standardized way to assess post-surgical complications. Additional factors being studied include:
Where Is the Study Being Conducted?
The study is being conducted in **ten major hospitals across Spain**:
How Long Will the Study Last? The study will take **two years** to complete, and patients will be followed for **three years** after surgery to track long-term outcomes.
Why Is This Study Important for Patients? For patients undergoing PD, this study will provide essential information about the risks and benefits of robotic versus open surgery. The findings will help doctors determine the best surgical approach, leading to improved safety, faster recovery, and better long-term health outcomes.
If you are a patient facing this type of surgery, participating in this study could contribute to valuable medical knowledge while ensuring that you receive a carefully monitored treatment plan.
Introduction
Pancreatoduodenectomy (PD), commonly known as the Whipple procedure, is a complex surgical procedure used to treat pancreatic, bile duct, and duodenal diseases, including cancer. Traditionally, this surgery has been performed using an open approach (PDA), but recent advancements in minimally invasive techniques have introduced the robotic approach (PDR) as a potential alternative.
Minimally invasive robotic surgery may offer benefits such as reduced blood loss, shorter hospital stays, and potentially lower complication rates. However, there is limited high-quality evidence comparing the outcomes of robotic PD versus open PD. This national, multicenter, randomized clinical trial aims to provide clear answers by analyzing postoperative complications and overall patient outcomes.
Primary Objective
Evaluate postoperative complications using the CCI within 90 days after surgery.
Objectives This clinical trial aims to compare two different surgical approaches, PDR and PDA, in relation to postoperative morbidity within 90 days following surgery. Morbidity is assessed using the Complication Index (CCI) (www.assesssurgery.com). The primary objective is to measure CCI®, which tracks complications up to 90 days after surgery. Secondary objectives include intraoperative variables (e.g., blood loss, operative time, and conversion), postoperative morbidity (e.g., pancreatic-specific complications as defined by ISGPS), oncological outcomes in cases of malignancy (radicality, lymph node removal, and time until adjuvant chemotherapy), healthcare resource utilization (length of stay, readmissions, ICU stay), and quality of life and recovery post-surgery.
Secondary Objectives
Intraoperative outcomes: Blood loss, operative time, and conversion rates from robotic to open surgery.
Postoperative morbidity: Evaluated using the International Study Group of Pancreatic Surgery (ISGPS) definitions.
Oncological outcomes (for cancer patients): Tumor clearance, number of lymph nodes removed, and time to adjuvant chemotherapy.
Healthcare resource utilization: Hospital stay, ICU admission, and hospital readmissions.
Quality of life and recovery after surgery.
Hypothesis The PDR surgical procedure demonstrates non-inferiority in the post-operative CCI score up to 90 days after surgery.
Materials and Methods
Study Design
This is a national, multicenter, randomized, prospective clinical trial with parallel groups comparing patients undergoing PD for any cause. Patients will be randomized into two groups:
Group 1: PDR Group 2: PDA The study will span 2 years. The research will be conducted in centers with an annual volume of at least 30 pancreatic resections (distal and cephalic) and surgeons with personal experience of at least 30 PDRs annually. A minimum of 30 pancreatic resections includes at least 20 pancreatoduodenectomies annually.
Sample Size This is a non-inferiority 2:1 study. According to previous studies, a clinically relevant mean difference in CCI is 7.5, while the average standard deviation is approximately 20 in major abdominal surgeries. A total of 120 patients will need to be enrolled in the trial (40 open group and 80 for robotic group), accounting for a 5% dropout rate, with an alpha error of 5% and a beta error of 20%.
Data Collection
Clinical Data Postoperative complications will be classified and evaluated according to the Clavien-Dindo classification (I to V) and the CCI numeric scale (www.assesssurgery.com). Major complications are those rated IIIa or higher. Complications, readmissions, and mortality will be measured up to 90 days.
Safety Assessment of Procedures
Both techniques, PDR and PDA, will be evaluated for adverse events. The following complications will be recorded in the Clinical Data Record (CRD):
Blood loss and need for transfusion during the procedure Postoperative hemorrhage Postoperative transfusion Biliary fistula Need for re-intervention Need for readmission Postoperative death Economic Data Economic data will be collected based on the single cost assigned to each procedure, calculated using the RECH system (Spanish Hospital Cost Network: https://www.rechosp.org). The costs will be derived from the National Health System's (SNS) diagnostic-related groups (DRG). The total cost will be calculated by multiplying the number of resource units used by the unit cost.
Measures to Minimize Bias Two main limitations are anticipated. The first concerns variability in surgical techniques among the surgeons. To minimize this, a meeting of all participating centers will be held to standardize surgical techniques. Furthermore, quality control will involve sending a video of the PDR procedure from each surgeon for evaluation.
The second limitation relates to patient recruitment. To address this, a conservative estimate of potential candidates was made, and centers with high volumes of pancreatic resections (at least 30 per year, including 20 pancreatoduodenectomies) have been selected.
Randomization Randomization will be performed using block assignment stratified by center, ensuring balanced groups within each participating hospital. Randomization between the robotic and open arms will occur before surgery with a 2:1 ratio (2 Robotic and 1 Open) using an online system.
Blinding This study will be single-blinded, meaning patients will not be aware of which group they belong to. After surgery, a cover will be applied to the abdominal wall so patients cannot see whether they had a robotic or open procedure.
Surgical Procedures
PDA:
The procedure begins with a bilateral subcostal incision. After initial exploration, if no distant disease is found, a PD will be performed. Reconstruction follows after the surgical specimen is removed.
PDR:
The procedure starts with robotic trocar placement, along with up to two additional laparoscopic trocars. Surgical steps follow the PDA procedure, but the specimen is removed through a mini-incision. Hybrid techniques (laparoscopic resection and robotic reconstruction) are excluded.
Data Recording Study variables will be stored in an online data collection form (CRD), which will automatically transfer data to a database. The system used for this will be Red Cap. The investigators and study monitor will have digital access to the Red Cap database to include new patients and review data during follow-up. Patient names will not appear in the database to ensure confidentiality. A subject code will be used for anonymity, and an identification register will link the code to the patient's medical record.
Statistical Analysis Data will be analyzed using IBM SPSS Statistics for Windows version 24.0 (IBM Corp.). Statistical tests such as Student's T-test, Mann-Whitney U test, Chi-square, and Fisher's exact test will be employed. Categorical data will be presented as frequency and percentage, and continuous data as mean, standard deviation, or median with interquartile range. Subgroups will be analyzed using Chi-square, Mann-Whitney U, and Kruskal-Wallis tests, with p\<0.05 indicating statistical significance.
Ethical Aspects The study will be registered on www.controlled-trials.com and will follow the ethical principles of the Declaration of Helsinki (2013) and Good Clinical Practice (GCP). Informed consent will be obtained from all participants, and the study will be reviewed by an Ethics Committee. The protocol will be registered on clinicaltrial.gov. Confidentiality will be maintained, and data will not be shared with third parties without consent.
Sample Management and Confidentiality Only necessary biological samples will be taken, with all patient data stored pseudonymized to ensure confidentiality. The study will comply with GDPR and local privacy laws.
Funding Funding for the study will be requested from the Spanish Association of Surgeons (AEC) for a total of €10,000, which will be used for insurance and monitoring.
Monitoring and Auditing The study will be monitored by clinical investigators and a data manager for periodic center audits.
Public Disclosure and Publication Results will be submitted to a high-impact medical journal, with authorship based on participant center recruitment volume. The study's findings will also be published in scientific journals following local regulations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Robotic pancreatoduodenectomy is performed under the robotic da Vinci system where at least the pancreatic and biliary anastomosis is performed throughout this approach.
Procedure: Robotic pancreatoduodenectomy
open pancreatoduodenectomy is performed through a laparotomy following the standard criteria for this type of surgery.
Procedure: open pancreatoduodenectomy
A Robotic approach pancreatoduodenectomy is performed on patients
An open approach for pancreatoduodenectomy is performed
Complication Index
Morbidity is assessed using the Complication Index (CCI) (www.assesssurgery.com). The primary objective is to measure CCI®, which tracks complications up to 90 days after surgery.
Time frame: up to 90 days after surgery
Cost effectiveness
Economic data will be collected based on the single cost assigned to each procedure, calculated using the RECH system (Spanish Hospital Cost Network: https://www.rechosp.org). The costs will be derived from the National Health System's (SNS) diagnostic-related groups (DRG). The total cost will be calculated by multiplying the number of resource units used by the unit cost. Effectiveness will be used with the EQ-5D-5L using the QALY model
Time frame: 3 months after surgery
Tumor clearance
pancreatic stump margins defined as R0, R1 or R2
Time frame: until the end of the study
operative time
Duration of the operation in minutes.
Time frame: during the surgery
Blood loss
intraoperative blood loss in ml
Time frame: during the surgery
Conversion to open surgery
This is only for the robotic approach where conversion to open occurred
Time frame: during surgery
Pancreatic Fistula
collection of data of pancreatic fistula according to International Study Group of Pancreatic Surgery (ISGPS) : Type A, B or C
Time frame: after surgery up to 90 days from operation
EORTC QLQ-C30
scale of quality if life
Time frame: before and after surgery at 30 and 90 days
QoR-15
test of quality of recuperation after surgery
Time frame: after surgery at 30 and 90 days
Plan to share: No — I do not want to be contacted by commercial industry regarding this study
Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.
Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 24 months is below that.
Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital del Mar